Marie Skłodowska-Curie Action
Innovative Training Networks (ITN)
2016-2020

ZoBio is a small CRO (Contract Research Organization) that provides research services in the field of Fragment-Based Lead Discovery (FBLD) to the biotech and pharma industries. ZoBio has expertise in 3 areas: the production of high quality, functional proteins for biophysics and structural biology, the use of NMR (TINS) and Biacore to screen fragment libraries for ligands specific to a desired target and NMR and X-ray structural biology methods to solve the 3D structure of small molecules bound to proteins. ZoBio is well equipped for protein production and characterization, including isotope labelling for protein observed NMR. The company also possesses a unique, proprietary collection of drug fragments and is the exclusive licensee of the patented TINS fragment screening technology. NMR methods are complimented by Biacore T200 and 4000 instruments for real time analysis of ligand protein interactions. In addition, ZoBio has extensive access to NMR facilities including 850 & 650 MHz NMR spectrometers equipped with cryoprobes.

 

Website link: ZoBio
             

Staff involved in this project:

Dr. Gregg Siegal

Dr. Gregg Siegal obtained his Ph.D. on studies of eukaryotic DNA replication at the University of Rochester in the USA under the supervision of Professor Robert Bambara. Subsequently he did a post-doc in the laboratories of Professor Kurt Wüthrich at the ETH in Switzerland and Professor Paul Driscoll at the Ludwig Institute of Cancer Research in the UK. It was during his post-Doctoral work that Dr. Siegal was exposed to NMR as a tool for both structural biology and drug discovery. He moved to Leiden University in 1997 where he received a Dutch Royal Society Fellowship to form his own research group. His current research interests focus on the development and application of innovative drug discovery technologies. In 2004 he spun out the company ZoBio to commercialize the TINS ligand screening technology developed in his group and presently serves as the Chief Executive Officer in addition to his position within the University.

 

 

 

 

 

 

 

Dr. Dipen Shah

Dr. Dipen Shah did his Ph.D. with Gregg Siegal on “NMR Structural Studies of Protein-Small Molecule Interactions. For the past 3 years he has worked as a scientist at ZoBio. His expertise lies in preparing proteins for structural biology and ligand discovery/validation. In addition, Dipen has pursued graduate courses in project management.

 

 

 

 

 

 

Dr. Oscar van Linden

Dr. Oscar van Linden obtained his Ph.D. with Prof. Iwan de Esch at the VUA in collaboration with Gregg. Oscar is a synthetic/medicinal/computational chemist with particular expertise in kinases.

 

 

 

 

 

 

 

 

Dr. Eiso AB

Dr. Eiso AB obtained his Ph.D. at the University of Groningen (NL) and post-Doc’ed at Utrecht University. He is one of the world’s leading experts on calculating the structure of proteins and protein-small molecule complexes from NMR data.

 

 

 

 

 

 

 

 


Lijndik